Originally presented July 24, 2019 as part of the UNC Cancer Network Medical and Surgical Oncology Lecture Series. Course expired October 1, 2020.
This is a Non-Credit course and does NOT offer continuing education credits.
Presenters
Autumn McRee, MD
Associate Professor, Division of Hematology/Oncology
Director, Clinical Trials for GI Oncology
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill
Emily Ray, MD, MPH
Nominated Clinical Assistant Professor
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill
Best of ASCO 2019: Gastrointestinal and Breast Cancers
The American Society of Clinical Oncology (ASCO) hosts an annual conference that features some of the latest oncology research. Join us as our speaker highlights some of the top presentations from this year’s ASCO conference. This lecture focuses on the top research for Gastrointestinal and Breast Cancers at the 2019 ASCO conference.
Learning Outcomes
- Explain the role of PARP inhibition in treating metastatic pancreatic cancer with germline BRCA mutations
- Discuss whether FOLFOXIRI should be considered 1st line standard of care in metastatic colorectal cancer
- Describe neoadjuvant and adjuvant therapy options for patients with HER2+ breast cancer
- Identify the principal findings of the MONALEESA-7 trial of endocrine therapy with or without ribociclib
Accreditation
This is a Non-Credit course and does NOT offer continuing education credits.
Disclaimer
Please note: This course was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. Questions about personal health should always be referred to a physician or other health care professional.